Séronie-Vivien S, Pieroni L, Galteau M-M, Carlier M-C, Hanser A-M, Cristol J-P
Departement de biologie clinique, Institut Claudius Regaud, Université Paul Sabatier, Toulouse, France.
Ann Biol Clin (Paris). 2008 May-Jun;66(3):263-8. doi: 10.1684/abc.2008.0226.
Since 2005, international guidelines propose a stadification for chronic renal failure based on the glomerular filtration rate (GFR) value. The performance of the creatinine-based equations allowing the estimation of GFR and the bias of the creatinine measurements is, more than ever, a crucial issue. The consequences for the clinical biologists are of importance. First, the Cockcroft-Gault formula must be replaced by the four variable-MDRD equation. Second, the biologists must chose from the "175" and the "186" versions of the MDRD equation. The first one fits the creatinine methods which are traceable to the reference method (liquid or gas chromatography coupled to mass spectrometry). The second equation must be used for creatinine methods, which are not traceable to the reference method. Today, only some enzymatic methods can prove that they are traceable to the reference method. For the colorimetric methods, future is inclear.
自2005年以来，国际指南建议根据肾小球滤过率（GFR）值对慢性肾衰竭进行分期。基于肌酐的方程用于估算GFR的性能以及肌酐测量的偏差，比以往任何时候都更是一个关键问题。这对临床生物学家来说具有重要意义。首先，Cockcroft-Gault公式必须被四变量MDRD方程取代。其次，生物学家必须从MDRD方程的“175”版本和“186”版本中进行选择。第一个版本适用于可溯源至参考方法（液相或气相色谱-质谱联用）的肌酐检测方法。第二个方程必须用于不可溯源至参考方法的肌酐检测方法。如今，只有一些酶法能够证明它们可溯源至参考方法。对于比色法，前景尚不明朗。
